Literature DB >> 19238792

Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues.

Paul A Morcos1, Yongfu Li, Shan Jiang.   

Abstract

We have developed a new transporter structure that provides effective delivery of Morpholino antisense oligomers into a wide variety of tissues in living mice. This transporter comprises a dendritic structure assembled around a triazine core which serves to position eight guanidinium head groups in a conformation effective to penetrate cell membranes. This transporter structure is conjugated to a Morpholino oligomer to form a delivery-enabled product referred to as a Vivo-Morpholino. Vivo-Morpholinos are shown to effectively enter and function within cultured cells in the presence of 100% serum using a rigorous positive test system based on correction of a defined splicing error in a pre-messenger RNA. In addition, Vivo-Morpholinos are demonstrated to enter into a wide variety of tissues in a similar positive test system in transgenic mice, as evidenced by correction of the targeted splicing error in all tissues assessed, including near-complete splice correction in the small intestine, colon, stomach, liver kidney, and a number of muscles. Finally, Vivo-Morpholinos, which target the exon-skipping of exon 23 harboring a premature termination codon in the mdx mouse model, effectively restore the reading frame of dystrophin and restore expression of a functional dystrophin protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19238792     DOI: 10.2144/000113005

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  91 in total

1.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  Oocyte-type linker histone B4 is required for transdifferentiation of somatic cells in vivo.

Authors:  Nobuyasu Maki; Rinako Suetsugu-Maki; Shozo Sano; Kenta Nakamura; Osamu Nishimura; Hiroshi Tarui; Katia Del Rio-Tsonis; Keita Ohsumi; Kiyokazu Agata; Panagiotis A Tsonis
Journal:  FASEB J       Date:  2010-05-11       Impact factor: 5.191

4.  Disruption of KATP channel expression in skeletal muscle by targeted oligonucleotide delivery promotes activity-linked thermogenesis.

Authors:  Siva Rama Krishna Koganti; Zhiyong Zhu; Ekaterina Subbotina; Zhan Gao; Ana Sierra; Manuel Proenza; Liping Yang; Alexey Alekseev; Denice Hodgson-Zingman; Leonid Zingman
Journal:  Mol Ther       Date:  2015-02-04       Impact factor: 11.454

5.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

6.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

7.  Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia.

Authors:  Kotoka Nakamura; Liutao Du; Rashmi Tunuguntla; Francesca Fike; Simona Cavalieri; Tomohiro Morio; Shuki Mizutani; Alfredo Brusco; Richard A Gatti
Journal:  Hum Mutat       Date:  2011-11-09       Impact factor: 4.878

8.  Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.

Authors:  Eugene J Wyatt; Alexis R Demonbreun; Ellis Y Kim; Megan J Puckelwartz; Andy H Vo; Lisa M Dellefave-Castillo; Quan Q Gao; Mariz Vainzof; Rita C M Pavanello; Mayana Zatz; Elizabeth M McNally
Journal:  JCI Insight       Date:  2018-05-03

9.  Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges.

Authors:  Michael T Lovci; Dana Ghanem; Henry Marr; Justin Arnold; Sherry Gee; Marilyn Parra; Tiffany Y Liang; Thomas J Stark; Lauren T Gehman; Shawn Hoon; Katlin B Massirer; Gabriel A Pratt; Douglas L Black; Joe W Gray; John G Conboy; Gene W Yeo
Journal:  Nat Struct Mol Biol       Date:  2013-11-10       Impact factor: 15.369

10.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.